TY - CHAP M1 - Book, Section TI - Glucagon A1 - Howland, Mary Ann A1 - Smith, Silas W. A2 - Nelson, Lewis S. A2 - Howland, Mary Ann A2 - Lewin, Neal A. A2 - Smith, Silas W. A2 - Goldfrank, Lewis R. A2 - Hoffman, Robert S. PY - 2019 T2 - Goldfrank's Toxicologic Emergencies, 11e AB - The traditional role of glucagon was to reverse life-threatening hypoglycemia in patients with diabetes unable to receive dextrose in the outpatient setting. However, in clinical toxicology, glucagon is used early in the management of β-adrenergic antagonist and calcium channel blocker toxicity to increase heart rate, contractility, and blood pressure by increasing myocardial cyclic adenosine monophosphate (cAMP) via a non–β-adrenergic receptor mechanism of action. The use of glucagon is based primarily on animal studies as well as human case series and case reports. The effects of glucagon are often transient. SN - PB - McGraw-Hill Education CY - New York, NY Y2 - 2024/10/13 UR - accessemergencymedicine.mhmedical.com/content.aspx?aid=1163002685 ER -